Although early studies utilizing broad-spectrum HDAC inhibitors showed beneficial effects in different HD mouse models [4], current ideology suggests that subtype-selective inhibitors may prove more beneficial for the treatment of neurological disorders, as these compounds might have fewer harmful side effects, caused by global inhibition of all HDAC proteins [5]. The gene discussed is HDAC9; the disease is Huntington disease.